BRAF and neoplasm: To investigate whether inhibition of ERK activation prevents TRIM63 phosphorylation and IRF-8 degradation, we found that treatment of BRAF-mutant tumor cells with Dabrafenib and Vemurafenib suppressed TRIM63 phosphorylation at S69 while concurrently increasing IRF-8 protein levels (Fig. 4J, K).